Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.503 USD | +2.03% | +3.69% | -7.42% |
Mar. 22 | Sangamo Therapeutics Prices $24 Million Registered Direct Offering | MT |
Mar. 14 | Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says | MT |
Financials (USD)
Sales 2024 * | 36.94M | Sales 2025 * | 64.14M | Capitalization | 104M |
---|---|---|---|---|---|
Net income 2024 * | -109M | Net income 2025 * | -82M | EV / Sales 2024 * | 3.93 x |
Net Debt 2024 * | 40.79M | Net Debt 2025 * | 129M | EV / Sales 2025 * | 3.64 x |
P/E ratio 2024 * |
-1.01
x | P/E ratio 2025 * |
-1.63
x | Employees | 405 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.29% |
Latest transcript on Sangamo Therapeutics, Inc.
1 day | +2.03% | ||
1 week | +3.69% | ||
Current month | -24.95% | ||
1 month | -21.61% | ||
3 months | +11.21% | ||
6 months | +4.79% | ||
Current year | -7.42% |
Managers | Title | Age | Since |
---|---|---|---|
Alexander Macrae
CEO | Chief Executive Officer | 61 | 16-05-31 |
Director of Finance/CFO | 46 | 19-02-28 | |
Gregory Davis
CTO | Chief Tech/Sci/R&D Officer | - | 20-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Peg Horn
BRD | Director/Board Member | 61 | 22-12-14 |
James Meyers
BRD | Director/Board Member | 58 | 19-11-21 |
H. Parker
CHM | Chairman | 68 | 14-06-18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.66% | 2 M€ | -25.75% | ||
0.49% | 16 M€ | -8.49% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 0.503 | +2.03% | 1,005,923 |
24-04-24 | 0.493 | -5.36% | 1,157,568 |
24-04-23 | 0.5209 | +2.12% | 2,278,588 |
24-04-22 | 0.5101 | -0.27% | 1,267,414 |
24-04-19 | 0.5115 | +5.44% | 1,050,146 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.42% | 104M | |
-2.26% | 103B | |
+1.41% | 95.71B | |
+0.93% | 22.02B | |
-17.84% | 20.9B | |
-11.11% | 17.85B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+4.55% | 13.86B | |
+32.11% | 12.04B |
- Stock Market
- Equities
- SGMO Stock